☆ 4.7 Meeting Abstract

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).

JOURNAL OF CLINICAL ONCOLOGY (2005)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 23, Issue 16, Pages 380S-380S

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2005.23.16_suppl.lba4510

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.